FDA Approves MOVANTIK (naloxegol) Tablets

FDA APPROVES MOVANTIK™ (naloxegol) TABLETS C-II FOR THE TREATMENT OF OPIOID
-INDUCED CONSTIPATION IN ADULT PATIENTS WITH CHRONIC NON-CANCER PAIN

AstraZeneca today announced that the US Food and Drug Administration (FDA)
approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral
peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the
treatment of opioid-induced constipation (OIC), in adult patients with chronic,
non-cancer pain.

Opioids play an important role in chronic pain relief and millions of patients
are treated with them in the United States each year. They work by binding to mu
-receptors in the central nervous system, but they also bind to mu-receptors in
the gastrointestinal tract, which can result in patients suffering from OIC.

“The FDA approval of MOVANTIK provides a new treatment option for adult patients
with chronic non-cancer pain suffering from opioid-induced constipation, a
common side effect of opioid therapy,” said Dr. Briggs Morrison, Executive Vice
President, Global Medicines Development & Chief Medical Officer, AstraZeneca.
“We are pleased to provide physicians and their patients with a once-daily oral
treatment supported by a robust clinical programme.”

The FDA approval of MOVANTIK was based on data from the KODIAC clinical
programme, which is comprised of four studies: KODIAC-4, -5, -7 and -8. KODIAC-4
and -5 were both placebo controlled, double-blind, 12 week studies assessing
safety and efficacy, while KODIAC-7 was a 12 week safety extension to KODIAC-4,
and KODIAC-8 was a 52 week open label, long-term safety study.

MOVANTIK is expected to be available to patients in the first half of 2015.
MOVANTIK is currently a schedule II controlled substance because it is
structurally related to noroxymorphone. During the review of the New Drug
Application, the FDA evaluated the abuse potential of MOVANTIK and the approved
labelling indicates that MOVANTIK has no risk of abuse or dependency.
AstraZeneca submitted a petition for the descheduling of MOVANTIK to the US Drug
Enforcement Administration (DEA) in March 2012, which was accepted for review
and will be considered by the DEA as part of the process for addressing the
descheduling request.

Results from KODIAC-4and -5were published in the New England Journal of Medicine
on 19 June 2014. Naloxegol is also under regulatory review by the European
Medicines Agency (EMA).

About MOVANTIK™ (naloxegol) tablets C-II

MOVANTIK™ (naloxegol) is the first FDA approved once-daily peripherally-acting
mu-opioid receptor antagonist (PAMORA) specifically designed for the treatment
of opioid-induced constipation (OIC) in adult patients with chronic non-cancer
pain. In the Phase III clinical studies, MOVANTIK was administered as a once
-daily tablet and was designed to block the binding of opioids to opioid
receptors in tissues such as the gastrointestinal (GI) tract.

MOVANTIK is part of the exclusive worldwide licence agreement announced on 21
September 2009 between AstraZeneca and Nektar Therapeutics. MOVANTIK was
developed using Nektar’s oral small molecule polymer conjugate technology.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)

Jacob Lund                                 +46 8 553 260 20 (Sweden)

Michele Meixell                           + 1 302 885 6351 (US)

Investor Enquiries

Karl Hård                                    +44 20 7604 8123  mob: +44 7789
654364

Jens Lindberg                                                              mob:
+44 7557 319729

Anthony Brown                           +44 20 7604 8067   mob: +44 7585 404943

Eugenia Litz                                +44 20 7604 8233   mob: +44 7884
735627

16 September 2014

-ENDS-